Neuropeptide Y1 receptor antagonism protects β-cells and improves glycemic control in type 2 diabetes

• Váldodahkkit: Chieh-Hsin Yang (Dahkki), Danise Ann-Onda (Dahkki), Xuzhu Lin (Dahkki), Stacey Fynch (Dahkki), Shaktypreya Nadarajah (Dahkki), Evan G. Pappas (Dahkki), Xin Liu (Dahkki), John W. Scott (Dahkki), Jonathan S. Oakhill (Dahkki), Sandra Galic (Dahkki), Yanchuan Shi (Dahkki), Alba Moreno-Asso (Dahkki), Cassandra Smith (Dahkki), Thomas Loudovaris (Dahkki), Itamar Levinger (Dahkki), Decio L. Eizirik (Dahkki), D. Ross Laybutt (Dahkki), Herbert Herzog (Dahkki), Helen E. Thomas (Dahkki), Kim Loh (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: Elsevier, 2022-01-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

Objectives: Loss of functional β-cell mass is a key factor contributing to poor glycemic control in advanced type 2 diabetes (T2D). We have previously reported that the inhibition of the neuropeptide Y1 receptor improves the islet transplantation outcome in type 1 diabetes (T1D). The aim of this stu...